OTCMKTS:NVZMY - NOVOZYMES A/S/S Stock Price, Forecast & News

$47.69

+0.24 (+0.51 %)

(As of 01/20/2020 10:41 AM ET)

Add

Compare

Today's Range

$47.34

Now: $47.69▼

$47.75

50-Day Range

$46.97

MA: $48.19▼

$49.32

52-Week Range

$39.96

Now: $47.69▼

$49.60

Volume16,612 shs

Average Volume11,991 shs

Market Capitalization$14.16 billion

P/E Ratio29.62

Dividend Yield1.06%

Beta0.76

Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry. Read More…

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorBasic Materials

Current SymbolOTCMKTS:NVZMY

Previous Symbol

CUSIPN/A

CIKN/A

Webhttp://www.novozymes.com/

Phone45-4446-0000

Debt

Debt-to-Equity Ratio0.23

Current Ratio1.29

Quick Ratio0.76

Price-To-Earnings

Trailing P/E Ratio29.62

Forward P/E Ratio30.38

P/E Growth2.39

Sales & Book Value

Annual Sales$2.28 billion

Price / Sales6.21

Cash Flow$1.72 per share

Price / Cash Flow27.70

Book Value$6.10 per share

Price / Book7.82

Profitability

EPS (Most Recent Fiscal Year)$1.75

Net Income$511 million

Net Margins21.08%

Return on Equity26.90%

Return on Assets14.94%

Miscellaneous

Employees6,427

Outstanding Shares297,000,000

Market Cap$14.16 billion

Next Earnings Date1/23/2020 (Estimated)

OptionableNot Optionable

Receive NVZMY News and Ratings via Email

Sign-up to receive the latest news and ratings for NVZMY and its competitors with MarketBeat's FREE daily newsletter.

(Ad)

Each week, an exclusive group of investors receives access to a simple list of 3 stocks to put on their radar for the week ahead.

You can sign up today to receive access to next week's watchlist -- generated by a proprietary methodology -- at no cost or obligation.

NOVOZYMES A/S/S (OTCMKTS:NVZMY) Frequently Asked Questions

What is NOVOZYMES A/S/S's stock symbol?

NOVOZYMES A/S/S trades on the OTCMKTS under the ticker symbol "NVZMY."

How often does NOVOZYMES A/S/S pay dividends? What is the dividend yield for NOVOZYMES A/S/S?

NOVOZYMES A/S/S announced an annual dividend on Thursday, February 7th. Stockholders of record on Friday, March 1st will be given a dividend of $0.504 per share on Tuesday, March 19th. This represents a dividend yield of 1.16%. The ex-dividend date is Thursday, February 28th. View NOVOZYMES A/S/S's Dividend History.

How were NOVOZYMES A/S/S's earnings last quarter?

NOVOZYMES A/S/S (OTCMKTS:NVZMY) posted its earnings results on Wednesday, October, 23rd. The biotechnology company reported $0.33 EPS for the quarter, missing the Zacks' consensus estimate of $0.43 by $0.10. The biotechnology company had revenue of $551.80 million for the quarter, compared to analysts' expectations of $565.21 million. NOVOZYMES A/S/S had a net margin of 21.08% and a return on equity of 26.90%. View NOVOZYMES A/S/S's Earnings History.

When is NOVOZYMES A/S/S's next earnings date?

NOVOZYMES A/S/S is scheduled to release their next quarterly earnings announcement on Thursday, January 23rd 2020. View Earnings Estimates for NOVOZYMES A/S/S.

What is the consensus analysts' recommendation for NOVOZYMES A/S/S?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NOVOZYMES A/S/S in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NOVOZYMES A/S/S.

Has NOVOZYMES A/S/S been receiving favorable news coverage?

News articles about NVZMY stock have been trending positive this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NOVOZYMES A/S/S earned a news impact score of 3.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for NOVOZYMES A/S/S.

Who are some of NOVOZYMES A/S/S's key competitors?

Some companies that are related to NOVOZYMES A/S/S include Biogen (BIIB), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), bluebird bio (BLUE), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT) and Crispr Therapeutics (CRSP).

What other stocks do shareholders of NOVOZYMES A/S/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NOVOZYMES A/S/S investors own include ManpowerGroup (MAN), TeamHealth (TMH), Novo Nordisk A/S (NVO), FOX (FOXA), Level One Bancorp (LEVL), Duke Energy (DUK), Emerson Electric (EMR), AT&T (T), Zayo Group (ZAYO) and DANSKE BK A/S/S (DNKEY).

Who are NOVOZYMES A/S/S's key executives?

NOVOZYMES A/S/S's management team includes the folowing people:

Mr. Peder Holk Nielsen, Pres & CEO (Age 63)
Dr. Prisca Havranek-Kosicek, CFO & Exec. VP of Corp. Functions (Age 44)
Mr. Thomas Videbaek, Exectuive VP & COO of Research, Innovation & Supply (Age 59)
Mr. Andrew Fordyce, Exec. VP of Food & Beverages (Age 56)
Mr. Anders Lund, Exec. VP of Household Care & Technical Industries (Age 46)

How do I buy shares of NOVOZYMES A/S/S?

Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NOVOZYMES A/S/S's stock price today?

One share of NVZMY stock can currently be purchased for approximately $47.69.

How big of a company is NOVOZYMES A/S/S?

NOVOZYMES A/S/S has a market capitalization of $14.16 billion and generates $2.28 billion in revenue each year. The biotechnology company earns $511 million in net income (profit) each year or $1.75 on an earnings per share basis. NOVOZYMES A/S/S employs 6,427 workers across the globe.View Additional Information About NOVOZYMES A/S/S.

What is NOVOZYMES A/S/S's official website?

The official website for NOVOZYMES A/S/S is http://www.novozymes.com/.

How can I contact NOVOZYMES A/S/S?

NOVOZYMES A/S/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at 45-4446-0000 or via email at [email protected]

MarketBeat Community Rating for NOVOZYMES A/S/S (OTCMKTS NVZMY)

Community Ranking:		1.8 out of 5 ()
Outperform Votes:		121 (Vote Outperform)
Underperform Votes:		219 (Vote Underperform)
Total Votes:		340

MarketBeat's community ratings are surveys of what our community members think about NOVOZYMES A/S/S and other stocks. Vote "Outperform" if you believe NVZMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVZMY will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/20/2020 by MarketBeat.com Staff

Your Ultimate Investing Toolkit

Just $1.00 for your first month.